Skip to main content
Premium Trial:

Request an Annual Quote

Medicare to Cover Myriad Genetics' BRACAnalysis for FDA-Approved CDx Indications

NEW YORK – The Centers for Medicare & Medicaid Services will now cover Myriad Genetics' BRACAnalysis CDx when used to identify prostate cancer patients with germline BRCA1 and BRCA2 mutations who may benefit from the PARP inhibitor olaparib (AstraZeneca/Merck's Lynparza), the company said on Friday.

In May, the US Food and Drug Administration approved olaparib for metastatic castration-resistant prostate cancer patients with germline or somatic mutations in homologous recombination repair genes who have progressed on enzalutamide and abiraterone. The agency simultaneously approved two companion diagnostics that may be used to identify best responders to this drug: Myriad's BRACAnalysis CDx to identify patients with germline BRCA1/2 mutations, and Foundation Medicine's FoundationOne CDx to identify patients with HRR-mutated genes in their tumors. 

Medicare contractors partaking in the MolDx program — Palmetto, CGS Administrators, Noridian, and Wisconsin Physicians Service Insurance Corporation — all recently issued local coverage articles that now list the four tumor types for which olaparib is approved alongside BRACAnalysis CDx as a companion diagnostic, including  breast, ovarian, pancreatic, and prostate cancer. The article also notes that the test is a covered companion diagnostic for not just olaparib in these settings, but other FDA-approved PARP inhibitors, such as talazoparib (Pfizer's Talzenna) and Rubraca (Clovis Oncology's rucaparib), in breast and ovarian cancer.  

"BRACAnalysis CDx is only covered for individuals diagnosed with ovarian cancer, breast cancer, pancreatic cancer, or prostate cancer and who have not been previously tested for BRCA mutations," the coverage article said. "MolDX will allow future FDA-approved and amended indications for this test."

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.